reference/12677946

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12677946

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1623
issn	1557-3265 1078-0432
issueIdentifier	5
pageRange	1613-1623
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	1613
bibliographicCitation	Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010 Mar 01;16(5):1613–23. doi: 10.1158/1078-0432.ccr-09-2483. PMID: 20179232.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_00085bdee2e8d80e7f60c7b82e539a2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_26da255e510e4a91ede1a518654e3708 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_09cfc6804bdfbd6de9da2d256c361281 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb2c729c08248bb5cce9c9a5b7540064 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ddf67f6260a128da85e61c37c023337f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aa8b08180160abd74b68ccd86b665189 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31f0f3836df4b4d77c4d41df99d5c08f http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1503-3123 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f498b4b4d5df32b174de599886447edb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c785cbf0ba5db3e772cc6a79fd0a64bb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b716c17cfd31e66c015f6b5e43a64f8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_735c8b9ba8509e8f94d00d3ef0283eb2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4814-8429 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6659356cf3c9afaf91119e40fbb116fc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f99ef72fbb2fe0e77c406dbb4c1c035e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6b215c1684742ac4eb8d316a4305f05e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_891729514ed269ce27b19e6a5a92fb5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97a6399a8abfb487c7db9045907a64ac
date	2010-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/20179232 https://doi.org/10.1158/1078-0432.ccr-09-2483
isPartOf	https://portal.issn.org/resource/ISSN/1557-3265 https://portal.issn.org/resource/ISSN/1078-0432 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
discusses	http://id.nlm.nih.gov/mesh/M0216971 http://id.nlm.nih.gov/mesh/M0507684 http://id.nlm.nih.gov/mesh/M0003316 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0208001 http://id.nlm.nih.gov/mesh/M0460512 http://id.nlm.nih.gov/mesh/M0002348
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001562Q000008 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D001562Q000009 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D000970Q000009
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D001562Q000493 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D002214 http://id.nlm.nih.gov/mesh/D048370Q000037 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000970Q000493 http://id.nlm.nih.gov/mesh/D048369Q000037 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7429 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10127622 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1c50845b337a3c11fa194521642a3ec8 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.11.24 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27924 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10030 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.7.12.2 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16214875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1117 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID61778 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8900

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129704387

Total number of triples: 79.